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Xenin-25 undergoes rapid enzyme metabolism following secretion. Early studies demonstrated 
bioactivity of a C-terminal hexapeptide fragment of xenin-25, namely xenin-6, which were 
enhanced through introduction of a reduced N-terminal peptide bond, to yield Ψ-xenin-6. The 
present study was undertaken to define the biological actions and potential antidiabetic 
properties of Ψ-xenin-6. In vitro enzymatic stability, insulin and glucagon secretory activity, 
as well as effects on beta-cell survival were determined. Studies in mice were used to assess 
the impact of Ψ-xenin-6 on glucose homeostasis and satiety. Ψ-xenin-6 was resistant to murine 
plasma degradation. In BRIN-BD11 cells and isolated murine islets, Ψ-xenin-6 significantly 
stimulated insulin secretion, and prominently enhanced the insulinotropic actions of GIP.  
Xenin-6 and Ψ-xenin-6 had no impact on glucagon secretion, although xenin-6 partially 
reversed the glucagonotropic action of GIP. Further in vitro investigations revealed that, similar 
to GLP-1, Ψ-xenin-6 significantly augmented proliferation of human and rodent clonal beta-
cells, whilst also fully protecting against cytokine-induced beta-cell cytotoxicity, with greater 
potency than xenin-25 and xenin-6. When administered to mice in combination with glucose, 
Ψ-xenin-6 significantly reduced glucose levels and enhanced glucose-induced insulin release, 
with a duration of biological action beyond 8 hours. Ψ-xenin-6 also significantly enhanced the 
glucose-lowering action of GIP in vivo. In overnight fasted mice, Ψ-xenin-6 exhibited satiety 
actions at both 25 and 250 nmol/kg. These data demonstrates that Ψ-xenin-6 is a metabolically 
stable C-terminal fragment analogue of xenin-25, with a metabolic action profile that merits 








The gut-derived hormone xenin-25, a 25 amino-acid peptide co-secreted from enteroendocrine 
K-cells with the incretin hormone glucose-dependent insulinotropic polypeptide (GIP), has 
previously been shown to reduce gastrointestinal transit and modulate energy balance (Cline et 
al., 2007; Leckstrom et al., 2009; Kerbel et al., 2018). Additional reports also suggest a role for 
xenin-25 in the regulation of pancreatic islet function and survival (Silvestre et al., 2003; Taylor 
et al., 2010; Martin et al., 2012; 2014; Gault et al., 2015; Parthsarathy et al., 2016; Khan et al., 
2017). In this regard, xenin-25 has also been shown to potentiate the insulinotropic actions of 
GIP (Wice et al., 2010; 2012), with suggested therapeutic potential for diabetes (Craig et al., 
2018). Notwithstanding this, the evident physiological importance of xenin-25 has been 
somewhat overlooked to date (Maryanovich et al., 2018), as well as the consequence of xenin-
25 enzymatic degradation. For instance, numerous regulatory gut-derived peptide hormones 
possess a dramatically altered biological action profile following enzymatic degradation in the 
circulation (Deacon, 2004; Mayorov et al., 2008; Lafferty et al., 2018).  
 For xenin-25, a number of C-terminally truncated metabolites have been characterised 
including, xenin 9-25, xenin 11-25, xenin 14-25 and xenin 18-25 (Martin et al., 2014). The 
biological significance of xenin 9-25, xenin 11-25 and xenin 14-25 is largely unknown (Martin 
et al., 2014). Interestingly, xenin 18-25, also referred to as xenin-8, has been shown to 
recapitulate the effects of the parent peptide at the level of the endocrine pancreas (Silvestre et 
al., 2003; Gault et al., 2015) and duodenum (Kaji et al., 2017), as well as potentiating the 
biological actions of GIP (Martin et al., 2014; 2016). This is extremely encouraging in terms 
of potential therapeutic application of xenin, since smaller peptide size will lead to reduced 
production costs, promote simpler drug formulation, which together will dramatically increase 
the overall commercial attractiveness. Following on from this, two very early studies in the 
xenin field had demonstrated bioactivity of a C-terminal hexapeptide of xenin-25, xenin-20-25 
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or also known as xenin-6 (Feurle et al., 1996; 2003). Encouragingly, enzymatic stability and 
biological efficacy of this xenin hexapeptide was substantially enhanced through the 
introduction of a reduced pseudopeptide bond (CH2NH) between Lys20 and Arg21 amino acid 
residues, to yield a Psi (Ψ) pseudopeptide analogue named Ψ-xenin-6 (Feurle et al., 2003). 
However, further application of these exciting observations with Ψ-xenin-6 have been missing 
until now. 
Therefore, the present study was conducted to further characterise Ψ-xenin-6, with a 
view to potential therapeutic application in the field of diabetes. As such, we initially confirmed 
enzymatic stability of Ψ-xenin-6 in plasma. In vitro and ex vivo effects of Ψ-xenin-6 on insulin 
and glucagon secretion from pancreatic BRIN-BD11 beta-cells, alpha TC1.9 cells as well as 
isolated mouse islets, as appropriate, were then evaluated. In addition, effects on rodent and 
human beta-cell proliferation and protection against cytokine-induced apoptosis were also 
assessed. Finally, the impact of Ψ-xenin-6 on glucose homeostasis, insulin section and satiety 
were examined in mice. Taken together, the results support further investigation of the potential 
therapeutic promise of Ψ-xenin-6 for diabetes.  
 
2. Materials and Methods 
 
2.1 Peptide synthesis and assessment of plasma enzymatic stability 
All peptides were purchased at greater than 95% purity. Native xenin-25 and xenin-6 was 
synthesised by GL Biochem (Shanghai, China). Ψ-xenin-6 was obtained from Saxon 
Biochemicals (Hannover, Germany). Before experimentation, peptides were characterised in-
house using HPLC and Matrix-assisted laser desorption ionisation time-of-flight (MALDI-
TOF) mass spectrometry (MS), as previously described (Gault et al., 2003). Enzymatic stability 
of peptides was evaluated in vitro using 18 h fasted murine plasma, as outlined previously 
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(Martin et al., 2012). Concisely, peptides (50 μg) were incubated with mouse plasma (50 μl) in 
the buffering agent triethanolamine–HCl (50 mM, pH 7.8) at 37 °C for 0, 120, 240 and 360 min 
and degradation profiles followed by HPLC, with MALDI-TOF MS analyses of collected 
HPLC peaks. 
 
2.2 In vitro and ex vivo insulin secretion 
In vitro insulin releasing activity of test peptides were assessed in rodent BRIN-BD11 beta-
cells, cultured and maintained as described (McClenaghan et al., 1996), using RPMI 1640 
media (Gibco Life Technologies Ltd), supplemented with 10% v/v foetal bovine serum 
(Gibco), 1% v/v antibiotics (0.1 mg/ml streptomycin and 100 U/ml penicillin) at 37oC in 5% 
atmospheric CO2. BRIN-BD11 cells were seeded into 24-well plates (150,000 cells per well) 
and allowed to attach overnight at 37oC. Prior to tests, cells were pre-incubated in Krebs–
Ringer bicarbonate buffer (KRBB) (pH 7.4) supplemented with 0.5% (w/v) BSA and 1.1 mM 
glucose (40 min; 37 °C). In the first set of experiments, cells were incubated (20 min) with test 
peptides (10-12 – 10-6 M) at 5.6 and 16.7 mM glucose, as appropriate. In a second set of 
experiments, BRIN-BD11 cells were incubated with peptides (10−12 to 10−6 M) in the presence 
of GIP (10−6 M) at 5.6 mM glucose for 20 mins. In a final set of experiments, BRIN BD11 cells 
were cultured for 48 hours under glucotoxic (22.2 mM glucose) conditions and insulinotropic 
effects  of GIP and xenin peptides (10−6 M) determined (n=8, 20 min incubation), as described 
previously from our laboratory (Pathak et al., 2014). After test incubations, aliquots of assay 
buffer (200 μl) were collected and stored at -20 °C prior to assessment of insulin 
concentrations. In a separate set of experiments, ex vivo insulinotropic effects of test peptides 
were assessed in NIH Swiss mouse islets, isolated using a collagenase-based method as 
previously described (McKillop et al., 2014). The experimental approach was similar to above 
at 16.7 mM glucose, but with a 60 min incubation period. In addition, at the end of the 
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experiment, 500 μl of acid-ethanol solution (1.5% [v/v] HCl, 75% [v/v] ethanol, 23.5% [v/v] 
H2O) was added (18 h, 4°C) to extract total islet cellular insulin content. All samples were 
stored at -20 °C prior to assessment of insulin concentrations by an in-house radioimmunoassay 
(RIA) (Flatt and Bailey, 1982). 
 
2.3 In vitro and ex vivo glucagon secretion 
α-TC1.9 cells were cultured in Dulbecco’s Modified Eagle Medium (DMEM) containing 25 
mM glucose and 2 mM L-glutamine supplemented with 10% (v/v) FCS and antibiotics (100 
U/ml penicillin and 0.1 g/l streptomycin). For experimentation, cells were cultured for 48 h in 
24-well plates at a cell density of 150,000 per well, to ensure attachment. Before 
commencement of secretory studies, cells were pre-incubated with 1 ml KRBB supplemented 
with 20 mM glucose for 1 h at 37°C. Following pre-incubation, cells were incubated (2 h, 37°C, 
1.4 mM glucose) with test peptides (10−6 M) alone or in combination with GIP (10−6 M). 
Supernatant (900 μl) was removed from each well and stored at -20°C until glucagon 
measurement.  Glucagon secretion from isolated mouse islets was conducted as described 
above, at 1.4 mM ambient glucose levels. Arginine (10 mM) was used as a positive control. 
All glucagon concentrations were measured by a commercially available chemiluminescent 
enzyme-linked immunosorbent assay (Millipore, Watford, UK), as previously described 
(Mohan et al., 2019).  
 
2.4 Cytotoxicity  
Toxicity of test peptides (10-6 M, 20 min) was determined by assessing levels of lactate 
dehydrogenase (LDH) release in BRIN-BD11 cells, as previously described (Srinivasan et al., 
2014), with dimethyl sulfoxide (DMSO, Sigma-Aldrich, UK) as a positive control. 
Concentrations of LDH were measured using a CytoTox96 non-radioactive cytotoxicity assay 
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kit (Promega, Madison, WI) according to the manufacturer’s protocol. This assay is highly 
sensitive and capable of accurately measuring the lower levels of LDH known to be present 
within pancreatic beta-cells (Schuit et al. 2001).  
 
2.5 In vitro beta-cell proliferation and apoptosis 
Rodent BRIN-BD11 and human 1.1B4 beta-cells were used to investigate effects of test 
peptides on beta-cell proliferation and protection against cytokine-induced apoptosis. GLP-1 
(10-8 and 10-6 M) was employed as a positive control for all studies. Ki-67 immunostaining was 
used to assess effects on proliferation. Briefly, cells were seeded onto coverslips at a density 
of 40,000 cells per coverslip and cultured overnight (18 h) at 37 °C, in the presence of peptides 
(10-8 and 10-6 M). Cells were then washed with PBS, and fixed using 4% paraformaldehyde. 
Following antigen retrieval with citrate buffer at 90 °C for 20 min, tissues were blocked using 
1.1% BSA for 30 min. Cells were then incubated with Ki-67 primary antibody, followed by 
Alexa Fluor® 594 secondary antibody. Coverslips were washed with PBS, mounted on slides 
for viewing using a fluorescent microscope (Olympus System Microscope) and photographed 
by DP70 camera adapter system. Proliferation frequency was expressed as percentage of total 
cells analysed.  For analysis of the ability of test peptides to protect against cytokine-induced 
apoptosis, cells were seeded as above. However, cells were also exposed to a cytokine-cocktail 
(IL-1β 300U/ml, IFN-γ 300 U/ml, TNF-α 40 U/ml; (Vasu et al., 2014) in the presence or 
absence of test peptides (10-8 and 10-6 M) for 2 h, with hydrogen peroxide as an additional 
control. TUNEL staining (Roche Diagnostics Ltd, UK) was performed to quantify beta-cell 
apoptosis, as previously described (Vasu et al., 2014). Apoptosis was expressed as percentage 





All animal studies were carried out using male NIH Swiss mice (12–14 weeks old, Envigo Ltd, 
UK), all housed individually in an air-conditioned room at 22 ± 2 °C with a 12 h light:12 h dark 
cycle. Animals were maintained on a standard rodent chow diet (10% fat, 30% protein and 
60% carbohydrate, Trouw Nutrition, UK), with ad libitum access to diet and water. All animal 
experiments were carried out in accordance with the UK Animal Scientific Procedures Act 
1986 and approved by the Ulster University Animal Welfare and Ethical Review Body 
(AWERB). 
 
2.7 Acute food intake studies 
Cumulative food intake was assessed in overnight fasted (18 h) mice following i.p. injection 
of saline vehicle (0.9% w/v NaCl) or test peptide (25 or 250 nmol/kg bw), and food intake 
measured at 30 min intervals for 180 mins. These doses were chosen based on the  observed 
appetite suppressive effects of xenin-25, and related metabolites, following peripheral 
administration in rodents (Taylor et al. 2010; Martin et al. 2014).    
 
2.8 Acute and persistent effects of peptides on glucose tolerance and insulin secretion  
Blood glucose and plasma insulin concentrations were determined immediately prior to and 
15, 30, 60 and 105 min after i.p. injection of glucose alone (18 mmol/kg bw) or in combination 
with test peptides (25 nmol/kg bw), as well as test peptides together with GIP (25 nmol/kg bw) 
in 4 h fasted mice. To assess duration of peptide action, mice were administered saline vehicle 
or test peptides (25 nmol/kg bw) at 2, 4, 8 or 12 h prior to an i.p. glucose challenge (18 mmol/kg 
bw) and blood glucose measured. 
 
2.9 Biochemical analysis  
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Blood samples were collected from the cut tip on the tail vein of conscious mice into chilled 
fluoride/heparin glucose micro-centrifuge tubes (Sarstedt, Numbrecht, Germany). Blood 
glucose was measured directly using a Contour blood glucose meter. For plasma insulin 
analysis, blood samples were collected into chilled fluoride/heparin glucose micro-centrifuge 
tubes (Sarstedt, Numbrecht, Germany) and immediately centrifuged using a Beckman 
microcentrifuge (Beckman Instruments, Galway, Ireland) for 1 min at 13,000 x g and stored at 
-20°C prior to insulin RIA (Flatt and Bailey, 1982). 
 
2.10 Statistical analysis  
Statistical analysis was completed using GraphPad PRISM (Version 5). Results are expressed 
as means ± SEM and data compared using repeated measures ANOVA followed by Student-
Newman-Keuls post-hoc test. Unpaired Student t-test was used where appropriate. Incremental 
plasma insulin and glucose area under the curve (AUC) were calculated using the trapezoidal 
rule with baseline subtraction. Groups of data were considered significant if p < 0.05. 
 
3. Results 
3.1 Peptide characterisation and plasma enzymatic stability  
In-house characterisation confirmed successful synthesis of test peptides (Table 1). In addition, 
Ψ-xenin-6 was completely resistant to plasma degradation following a 6 h incubation, whereas 
native xenin-6 had an estimated in vitro half-life of less than 2 h (Table 1). 
 
3.2 Insulin secretory actions  
In BRIN-BD11 cells, both xenin-6 and Ψ-xenin-6 displayed significant (p < 0.05 to p < 0.001) 
dose-dependent insulin secretory actions at 5.6 and 16.7 mM glucose concentrations when 
compared to respective glucose controls (Fig. 1A,B). Interestingly, at 5.6 mM glucose, Ψ-
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xenin-6 exhibited superior (p < 0.05) insulinotropic effects than native xenin-6 at all peptide 
concentrations tested, barring 10-8 M, and at 10−6 M in 16.7 mM glucose (Fig. 1A,B). The 
potent insulin-releasing actions of Ψ-xenin-6, with superiority (p < 0.01) over native xenin-6, 
were then confirmed in fully functional isolated murine islets (Fig. 1C). When xenin peptides 
were co-incubated with GIP in BRIN-BD11 cells, both xenin-6 and Ψ-xenin-6 significantly (p 
< 0.05 to p < 0.001) augmented the insulinotropic actions of GIP (Fig. 1D). In this regard, Ψ-
xenin-6 exhibited superior (p < 0.01 to p < 0.001) GIP-potentiating efficacy than xenin-6 at all 
concentrations examined (Fig. 1D). Under glucotoxic culture conditions, the insulin secretory 
responses of GIP, xenin-6 and Ψ-xenin-6 were significantly (p < 0.05 to p < 0.01) impaired 
(Fig. 1E). Interestingly, when xenin-6 was co-incubated with GIP, the insulinotropic response 
was not significantly different in BRIN BD11 cells cultured under normal or glucotoxic culture 
conditions (Fig. 1E). In contrast, although co-incubation with Ψ-xenin-6 and GIP under 
glucotoxic conditions augmented insulin secretion to a higher degree than co-incubation with 
xenin-6 and GIP, insulin secretion was reduced (p < 0.01) when compared to control cultures 
(Fig. 1E). None of the xenin peptides compromised BRIN-BD11 cell plasma membrane 
integrity, as displayed by lack of effects on lactate dehydrogenase levels following a 20-minute 
incubation at the highest (10-6 M) peptide concentration used in normal cells (Fig. 1F). 
 
3.3 Glucagon secretory actions  
As expected, arginine (10 mM) and native GIP (10-6 M) augmented (p < 0.001) glucagon 
secretion from α-TC1.9 cells at 1.4 mM glucose levels (Fig. 2A). Neither xenin-6 nor Ψ-xenin-
6 (both at 10-6 M) altered glucagon secretion (Fig. 2A). However, xenin-6 partially reversed 
the glucagonotropic actions of GIP, whereas Ψ-xenin-6 did not (Fig. 2A). The observations on 
glucagon secretion following incubation of arginine, GIP, xenin-6 and Ψ-xenin-6 in α-TC1.9 
cells were paralleled in isolated murine islets (Fig. 2B). In addition, whilst the ability of xenin-
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6 to reverse GIP-induced elevations of glucagon secretion was again apparent, this failed to 
reach significance in mouse islets (Fig. 2B). 
 
3.4 Beta-cell proliferation and protection against apoptosis 
Similar to GLP-1, Ψ-xenin-6 significantly (p < 0.001) augmented BRIN-BD11 and 1.1B4 beta-
cell proliferation at both 10-8 and 10-6 M (Fig. 3A,B). Xenin-25 only displayed beta-cell 
proliferative effects in BRIN-BD11 cells at a concentration of 10-8 M (Fig. 3A). Native xenin-
6 displayed no proliferative actions in 1.1B4 beta-cells (Fig. 3A,B), with a slight (p < 0.05) 
increase noted at 10-6 M in BRIN-BD11 cells (Fig. 3A). In relation to protection against 
cytokine-induced apoptosis, all test peptides reversed the detrimental DNA damaging effects 
of co-incubation with cytokines in BRIN-BD11 cells, but only at the highest concentration 
employed (Fig. 3C). In 1.1B4 beta-cells, Ψ-xenin-6 offered full protection against cytokine-
induced apoptosis at both 10-8 and 10-6 M, with benefits of GLP-1, xenin-25 and xenin-6 only 
observed at 10-6 M (Fig. 3D). In 1.1B4 cells Ψ-xenin-6 (10-6 M) reduced (p < 0.05) cytokine-
induced elevations of TUNEL staining to below control levels (Fig. 3D).  
 
3.5 Acute in vivo food intake  
At a dose of 25 nmol/kg, xenin-25 and Ψ-xenin-6 induced a significant (p < 0.05) reduction in 
food intake at 180 min post-injection in overnight fasted mice, when compared to saline 
controls (Fig. 4A). Interestingly, at a dose of 250 nmol/kg, only Ψ-xenin-6 exhibited appetite 
suppressive actions, evident at both 30 (p < 0.01) and 180 (p < 0.05) min post-injection (Fig. 
4B). Native xenin-6 had no effect on feeding at either of the doses employed (Fig. 4A,B). 
 
3.6 Acute glucose lowering and insulin releasing effects in mice 
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Administration xenin-6 or Ψ-xenin-6 in combination with glucose resulted in significantly (p 
< 0.05 to p < 0.001) decreased individual and overall 0-105 min AUC plasma glucose levels 
when compared to glucose alone control (Fig. 5A,B). Native GIP did decrease (p < 0.05) 
glucose levels at 30 min post-injection (Fig. 5A), but this did not translate to significant 
reductions in AUC values (Fig. 5B). When xenin-6 and Ψ-xenin-6 were administered in 
combination with GIP, there was a significant (p < 0.01 to p < 0.001) reduction in glucose 
levels at 15 and 30 min post-injection when compared to GIP alone (Fig. 5A). Reductions in 
overall AUC values when compared to GIP alone were only observed when GIP was combined 
with Ψ-xenin-6 (p < 0.05), but not xenin-6 (Fig. 5B). All treatments elevated (p < 0.05 to p < 
0.01) corresponding 0-105 min AUC plasma insulin concentrations (Fig. 5D). However, only 
Ψ-xenin-6 significantly (p < 0.01) increased individual plasma insulin levels, although this was 
only apparent at 105 min post-injection (Fig. 5C). There was no obvious augmentation of the 
insulinotropic actions of GIP by either xenin-6 or Ψ-xenin-6 (Fig. 5C,D). 
 
3.7 Persistent glucose lowering and insulin releasing effects in mice 
Administration of either xenin-6 or Ψ-xenin-6 2 h prior to glucose load, resulted in significantly 
reduced individual (p < 0.05 to p < 0.01) and AUC overall (p < 0.001) blood glucose levels 
when compared to saline control mice (Fig. 6A,B). Comparable observations were made when 
the peptides were injected 4 h before the glucose challenge (Fig. 6C,D), although Ψ-xenin-6 
was significantly (p < 0.05) more effective than xenin-6 (Fig. 6D). When administered 8 h prior 
to the glucose load, both xenin-6 and Ψ-xenin-6 reduced (p < 0.05 to p < 0.01) individual 
glucose levels at 30 min post-injection, but only Ψ-xenin-6 significantly (p < 0.01) decreased 
overall AUC glucose values (Fig. 6E,F). Both peptides failed to elicit any significant glucose-





Previous reports have established that chemical manipulation of the C-terminal hexapeptide of 
xenin-25, namely xenin-6, through introduction of a reduced pseudopeptide bond between 
Lys20 and Arg21, yields an enzymatically stabilised peptide with enhanced biological activity 
(Feurle et al., 2003). Similar enhanced metabolic stability and bioactivity has been observed 
following introduction of a reduced pseudopeptide bond in neurotensin (Lugrin et al., 1991), a 
peptide closely related to xenin (Feurle et al., 2002). Such effects are in complete harmony 
with previous studies from our laboratory, demonstrating enhanced stability and biological 
activity of an octapeptide C-terminal fragment of xenin-25 following rationally introduced 
amino-acid modifications (Parthsarathy et al., 2016; Martin et al., 2016). 
Consistent with this knowledge, in the present study xenin-25, xenin-6 and especially 
Ψ-xenin-6 evoked clear increases of insulin secretion from pancreatic BRIN-BD11 cells 
(Feurle et al., 1992; Taylor et al., 2010). Indeed, both xenin hexapeptides had comparable, or 
even enhanced, efficacy when compared to the parent peptide. Notably, Ψ-xenin-6 was 
significantly more efficacious than xenin-6 at 5.6 mM glucose, expect at 10-8 M, which is 
interesting and may require further study. The insulinotropic potency of the xenin peptides 
appeared to be somewhat reduced at higher glucose concentrations in BRIN BD11 cells, and 
this may be due to difficulties in assessing additive peptide effects in the face of increased 
insulin output by elevated glucose. Nonetheless, these observations corroborate that the C-
terminal hexapeptide of xenin-25 is capable of activating xenin related beta-cell signalling 
pathways. Indeed, insulin secretory studies using functional isolated mouse islets fully 
confirmed this concept. GIP-potentiating actions of xenin-25 are recognised at the level of the 
beta-cell (Wice et al., 2010; 2012 Martin et al., 2012; Parthsarathy et al., 2016), which were 
reproduced by xenin-6, and to a significantly greater magnitude by Ψ-xenin-6. In BRIN BD11 
cells cultured under glucotoxic conditions to mimic beta-cell stress encountered in diabetes 
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(Pathak et al., 2014), as would be expected, there was an impairment of the insulin‐releasing 
action of GIP and xenin-6 peptides. GIP-augmenting actions of the truncated xenin peptides 
were still observed under glucotoxic culture, especially in the case of xenin-6. Nonetheless, the 
more effective of the two compounds in terms of GIP-potentiation was Ψ-xenin-6, albeit with 
notably less efficacy than in normal beta-cells. In addition, Ψ-xenin-6 was the only peptide 
examined that significantly enhanced the glucose-lowering action of GIP in mice. Whilst the 
exact mechanism of xenin-induced GIP potentiation remains to be elucidated (Clemens et al., 
1997; Wice et al., 2010; Mazella et al., 2012), it does substantiate the idea that Ψ-xenin-6 
possess enhanced biological potency over xenin-6 (Feurle et al., 2003). It is also encouraging 
to note that the reduced pseudopeptide bond present within Ψ-xenin-6 had no detrimental 
impact in terms of beta-cell cytotoxicity.  
Based on previous observations of glucagonotropic effects of a C-terminal octapeptide 
fragment of xenin-25 (Silvestre et al., 2003), and evidence that GIP induces glucagon secretion 
under fasting glycaemic levels (Christensen et al., 2011), we sought to further examine this 
concept with Ψ-xenin-6. Unlike GIP, both xenin-6 and Ψ-xenin-6 were devoid of 
glucagonotropic actions in αTC1.9 cells and isolated rodent islets. This does slightly contrast 
with previous studies using xenin-8 in rodent islets, although in situ perfusion as opposed to 
static incubations was employed for this earlier study (Silvestre et al., 2003). In addition, the 
most prominent secretory effect of xenin-8 was noted to be potentiation of arginine- and 
carbachol-induced glucagon elevations (Silvestre et al., 2003). Given this, and the notable 
interactions between xenin and GIP (Martin et al., 2012; Wice et al., 2012; Chowdhury et al., 
2013; Hasib et al., 2016), the impact of co-incubation with the xenin-6 fragment peptides and 
GIP was considered. Interestingly, xenin-6, but not Ψ-xenin-6, had a strong tendency to reverse 
GIP-mediated increases in glucagon release. This is interesting, as both augmentation and 
blockade of glucagon receptor signalling has been advocated as being beneficial in diabetes 
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(Pathak et al., 2015; McShane et al., 2016). The difference in biological activity between the 
two xenin C-terminal hexapeptides is intriguing and presumably not related to the enhanced 
stability of Ψ-xenin-6 noted here and elsewhere (Feurle et al., 2002). It could also relate to 
structure/function complexities between the peptides, which would require more in-depth 
study.  However, the overall impact of xenin on GIP-induced alterations of glucagon secretion 
is of significant interest, since GIP infusion has been shown to prevent insulin-induced 
hypoglycaemia in humans (Christensen, 2016). Indeed, this may represent an important 
homeostatic metabolic mechanism of GIP (Christensen et al., 2011), where xenin may also 
play a key role, and could have particular relevance in the diabetes setting.  
Further to this, previous studies with xenin-25 have clearly highlighted potential 
benefits at the level of the pancreatic beta-cell. As well as enhancing insulin release and 
potentiating GIP-induced insulin release (Taylor et al., 2010; Wice et al., 2010; Martin et al., 
2012; 2014), the parent xenin peptide has been shown to promote pancreatic beta-cell growth 
and survival (Khan et al., 2017). Promisingly, Ψ-xenin-6 had similar, or even enhanced, beta-
cell proliferative and survival beneficial effects in both rodent BRIN-BD11 and human 1.1B4 
beta-cells. This is encouraging given that type 2 diabetes is a disease characterised by beta-cell 
loss (Halban et al., 2014), although the exact mechanisms of these xenin-induced beneficial 
effects still needs to be elucidated. Similar to previous reports (Mohan et al., 2018; 2019), 
baseline apoptosis rates were somewhat elevated in both beta-cell lines, representing a 
particularly challenging environment. As such, it may have been interesting to assess beta-cell 
survival benefits of Ψ-xenin-6 and xenin-6 under less severe beta-cell insults. However, the 
aforementioned positive effects of Ψ-xenin-6 on glucose homeostasis, insulin release and GIP 
potentiation, coupled with an in vivo duration of approximately 8 hours in mice, further 
promote its potential therapeutic value for diabetes. The observation of enhanced glucose 
homeostatic actions of combined GIP and Ψ-xenin-6 administration in mice, despite no 
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obvious augmentation of insulin secretion, likely reflects enhancement of the notable 
extrapancreatic glucose-lowering effects of GIP and xenin (Irwin and Flatt, 2015; Craig et al., 
2018). Furthermore, xenin has been suggested to supress food intake (Craig et al., 2018) and 
delay gastric emptying rate (Kim and Mizuno, 2010), which would also be complementary in 
the type 2 diabetes setting (Al-Goblan et al., 2014). In our hands, Ψ-xenin-6 induced small, but 
significant, appetite suppressive effects in mice at doses of 25 and 250 nmol/kg, whereas xenin-
6 was ineffective. Notably, physiological circulating concentrations of xenin are not well 
defined, and local tissue production of xenin has been documented outside of the gut (Khan et 
al., 2017). In addition, previous studies demonstrating prominent efficacy of xenin peptides to 
inhibit feeding have largely employed intracerebroventricular administration (Alexiou et al., 
1998; Cooke et al., 2009; Leckstrom et al., 2009; Bhavya et al., 2017; Kerbel et al., 2018), as 
opposed to peripheral application in the present study. This may suggest that efficient passage 
through the blood-brain barrier is critical for xenin-based peptides to positively modulate 
energy balance.  
In conclusion, these data substantiate the notion that Ψ-xenin-6 is a stable, long-acting 
xenin analogue that retains the full biological action profile of the parent peptide. Benefits of 
Ψ-xenin-6 on pancreatic islet cell function and survival, appetite suppression and GIP-
potentiation, coupled with a prolonged half-life, emphasise prospective therapeutic potential of 
this peptide for diabetes. Future studies should therefore evaluate the preclinical utility of Ψ-
xenin-6 in appropriate models of diabetes, both alone and in combination with established 
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Table 1. Amino acid sequence, theoretical and experimental masses as well as murine plasma half-lives of xenin peptides 
 




In vitro half-life 
(murine plasma) 
Xenin-6 H‐LYS‐ARG‐PRO‐TRP‐ILE‐LEU‐OH 812.2 812.0 < 2 h 
Ψ-xenin-6 H‐LYS-ψ‐ARG‐PRO‐TRP‐ILE‐LEU‐OH 798.1 798.5 > 6 h 
 
Amino acid sequence of peptides using three letter amino acid nomenclature. Peptide masses were calculated using MALDI-MS, as previously 
described (Gault et al., 2003). In vitro stability of peptides was evaluated using 18-h fasted murine plasma. Xenin-6 and Ψ-xenin-6 (50 μg) were 
incubated with mouse plasma (50 μl) in 50 mM triethanolamine–HCl for 0, 2, 4 and 6 h and degradation profiles followed by HPLC, with MALDI-




Fig. 1. Effects of Ψ-xenin-6 on insulin release from BRIN-BD11 cells (A,B,D,E) and isolated 
mouse islets (C) as well as LDH accumulation (F) in BRIN-BD11 cells. (A,B,D) BRIN-BD11 
were incubated (20 min) with a range of concentrations (10-12 to 10-6 M) of xenin-6 and Ψ-
xenin-6 alone (A,B) or in combination with GIP (D) in the presence of (A,D) 5.6 or (B) 16.7 
mM glucose. (C) Insulin release was measured in isolated mouse islets incubated (60 min) with 
of xenin-6 and Ψ-xenin-6 (10-8 and 10-6 M) at 16.7 mM glucose. (E) BRIN BD11 cells were 
cultured under glucotoxic (22.2 mM glucose) culture conditions for 48 h and then incubated 
(20 min) with (10-6 M) GIP, xenin-6 and Ψ-xenin-6 alone or in combination, as appropriate, in 
the presence of 5.6 mM glucose. (A-E) Insulin was measured using a RIA. (F) LDH 
accumulation was assessed in BRIN-BD11 cells following a 20 min incubation with 10-6 M 
xenin-25, xenin-6 or Ψ-xenin-6. Values represent means ± SEM (A,B,D n=8; C,E and n=4). 
*p < 0.05, **p < 0.01, ***p < 0.001 compared to respective glucose controls. ∆p < 0.05, ∆∆p < 
0.01 compared to (A,B) respective xenin-25 control or (E) same concentration of respective 
peptide treatment under normal culture conditions. πp < 0.05, ππp < 0.01, πππp < 0.001 compared 
to xenin-6. Φp < 0.05, ΦΦp < 0.01, ΦΦΦp < 0.001 compared to respective GIP control. 
 
Fig. 2. Effect of Ψ-xenin-6 on glucagon secretion from (A) αTC 1.9 cells and (B) isolated 
mouse islets. The effects of xenin-6 and Ψ-xenin-6 alone (10-6 M) or in combination with GIP 
(10-6 M) on glucagon secretion from (A) αTC 1.9 cells (120 min incubation) and (B) isolated 
mouse islets (60 min incubation) was assessed at 1.4 mM glucose. Glucagon was measured 
using an ELISA. Values represent means ± SEM (n=4). *p < 0.05, **p < 0.01, ***p < 0.001 




Fig. 3. Effect of Ψ-xenin-6 on proliferation and protection against apoptosis in rodent BRIN-
BD11 and human 1.1B4 beta cells. (A) BRIN-BD11 and (B) 1.1B4 beta-cells were incubated 
overnight (18 hours) with GLP-1, xenin-25, xenin-6 or Ψ-xenin-6 (each at 10-8 and 10-6 M). 
Proliferation was measured using Ki-67 immunocytochemistry. (C,D) TUNEL positive 
apoptotic cells were assessed following 2 h exposure to a cytokine cocktail (IL-1β 100 U/mL, 
IFN-γ 20 U/mL, TNF-α 200 U/mL) with or without co-culture in the presence of GLP-1, xenin-
25, xenin-6 or Ψ-xenin-6 (each at 10-8 and 10-6 M) in (C) BRIN-BD11 and (D) 1.1B4 beta-
cells. Values represent means ± SEM (n=4). *p < 0.05, **p < 0.01, ***p < 0.001 compared to 
respective media control.  
 
Fig. 4. Effects of Ψ-xenin-6 on cumulative food intake in 18 hour fasted mice. Cumulative 
food intake was measured in 18 h fasted mice at 30, 60, 90, 120, 150, 180 min after i.p. injection 
of saline vehicle (0.9% w/v NaCl), xenin-25, xenin-6 or Ψ-xenin-6 at (A) 25 and (B) 250 
nmol/kg bw. Values represent means ± SEM (n=8). *p < 0.05, **p < 0.01 compared to 
respective saline control. 
 
Fig. 5. Effects of xenin-6 and Ψ-xenin-6 alone as well as in combination with GIP on plasma 
glucose and insulin concentrations in mice. (A) Blood glucose and (C) plasma insulin 
concentrations were measured immediately before and 15, 30, 60 and 105 min after i.p. 
injection of glucose alone (18 mmol/kg bw) or in combination with GIP, xenin-6 or Ψ-xenin-
6, as well as combined injection of GIP and xenin-6 or Ψ-xenin-6 (each peptide injected at 25 
nmol/kg bw) in 4 h fasted mice. (B,D) Blood glucose and plasma insulin area under the curve 
(AUC) values for 0-105 min post injection are also shown. Values represent mean ± SEM for 
6 mice. *p < 0.05, **p < 0.01, ***p < 0.001 compared to glucose alone. ∆p < 0.05, ∆∆p < 0.01, 




Fig. 6. Persistent glucose lowering effects of Ψ-xenin-6 in mice. (A,C,E,G) Blood glucose 
concentrations were measured immediately before and 15, 30, 60 and 105 min following an 
i.p. glucose load (18 mmol/kg bw) in 4 h fasted mice injected with saline vehicle (0.9% w/v 
NaCl), xenin-6 or Ψ-xenin-6 (each at 25 nmol/kg bw) 2 (A), 4 (C), 8 (E) or 12 h (G) previously. 
(B,D,F,H) Blood glucose AUC values for 0-105 min post injection are also shown. Values 
represent mean ± SEM for 6 mice. *p < 0.05, **p < 0.01, ***p < 0.001 compared to glucose 
alone. ∆p < 0.05 compared to xenin-6. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
28 
 
 
 
 
29 
 
 
30 
 
 
 
31 
  
32 
 
 
33 
 
 
